Articles tagged with Cancer Medication
Scientists at MIT created a new cancer therapy that activates both the innate and adaptive immune systems to attack tumors. The treatment combines an antibody drug with IL-2, which boosts immune responses, resulting in complete tumor disappearance in 80-90% of mice.
Researchers at Queen's University Belfast have launched a revolutionary personalized treatment program to improve bowel cancer survival rates. The S-CORT Consortium will employ state-of-the-art techniques to define the genetic make-up of bowel cancer cells, collected from over 2,000 patients, and develop personalized care plans.
Recent studies in Cancer Cell and Trends in Immunology review the intricate relationship between the immune system and cancer. Research has shown that harnessing anti-tumor immunity can be a promising approach to treating various cancers.
Researchers discovered a previously invisible biological process that may be implicated in the rapid growth of some cancers. The new study reveals that a well-known cancer protein called mTOR can hand off its work to another protein, CDK1, when cells are dividing.
Moffitt scientists developed a novel technique to analyze the MDMX protein, revealing its auto-inhibitory segment that controls p53 activity. This discovery may help identify patients more likely to respond to an MDMX-targeted cancer drug.
A research team has identified a drug target for ATRA, a treatment for acute promyelocytic leukemia (APL), by targeting the Pin1 enzyme. The discovery offers a promising new way to fight aggressive or drug-resistant cancers by degrading cancer stem cells and blocking multiple cancer-driving pathways.
Scientists at the University of Southampton have developed a drug that can reverse resistance to immunotherapy in certain leukaemias and non-Hodgkin lymphomas. The new antibody, BI-1206, works by binding to a molecule called FcγRIIB and enhancing cancer killing, promising improved treatment outcomes for patients with blood cancers.
Researchers James P. Allison and Padmanee Sharma argue that combining targeted therapies with immunotherapy could be key to developing curative treatments for various cancer types, building on promising results from clinical trials.
Researchers at Scripps Research Institute have received a grant to investigate the Hippo-YAP signaling pathway in various cancers, including breast and colorectal cancer. The study aims to identify compounds targeting this pathway to combat cancer, with a focus on ultra-high-throughput screening resources.
Researchers at the University of Texas MD Anderson Cancer Center review the potential of combining genomically targeted therapies with immune checkpoint blockade drugs to attack cancer. The approach shows promise, but more support is needed to accelerate progress and minimize side effects.
Researchers have identified six chemical compounds that inhibit HuR, a protein promoting tumor growth. The findings hold promise for treating various cancers and could lead to a novel class of cancer therapies.
A new clinical trial results show that ibrutinib continues to control Waldenstrom's Macroglobulinemia, with a median overall response rate of 91% after 19 months of treatment. The disease shows sustained benefit in patients who survived for two years.
Uninsured cancer patients pay 2-43 times more than Medicare and private insurers for chemotherapy drugs, according to a new study. The study found significant price differences for expensive and inexpensive drugs alike.
According to a Northwestern University study, nearly 400,000 childhood cancer survivors in the US experience chronic health issues, including mental impairment, anxiety, and physical limitations. The majority face these problems five or more years after diagnosis, highlighting the need for comprehensive care.
Many cancers, including pancreatic cancer, enslave and deform mitochondria to create an environment conducive to tumor growth. Researchers found that blocking this process may lead to the growth of tumors.
Scientists have identified a small RNA molecule called miR-182 that can suppress cancer-causing genes in mice with glioblastoma, a deadly type of brain tumor. The new method uses nanotechnology to deliver the microRNA across the blood-brain barrier, targeting multiple oncogenes at once and increasing cancer cell death.
Researchers from USC Norris Comprehensive Cancer Center have discovered that herpesvirus proteins activate the RIG-I receptor through deamidation, a process that could be exploited to bolster immunity against infection. The study identifies the first enzyme responsible for protein deamidation in eukaryotes.
Scientists at CHOP use biodegradable nanoparticles to deliver anticancer drugs selectively to tumors, inhibiting growth and prolonging survival in animal models. The approach exploits the EPR effect, allowing for efficient delivery while avoiding toxicity in healthy tissues.
A new review emphasizes the need to decipher immune response dynamics to enhance cancer immunotherapy. Researchers suggest developing combination therapies and biomarker panels to increase treatment impact, as single biomarkers are unlikely to predict patient responses.
Researchers at UCSF identified a biological escape hatch that explains resistance to targeted drug treatment in lung cancer patients. Combining two compounds, erlotinib and PBS-1086, effectively wipes out cancer cells in mice implanted with cells from drug-resistant tumors.
Researchers at Nanyang Technological University (NTU) have found that Imatinib, a leukemia drug, can prevent and control the growth of colorectal tumours. The study suggests that short-term intermittent chemotherapies could be effective in treating colon cancer, reducing side effects associated with long-term treatment.
A new study provides experimental evidence that a drug inhibiting the EphB-signaling pathway effectively suppresses intestinal tumor development. The study suggests that this knowledge may lead to novel treatments for colorectal cancer patients.
Researchers at the University of Missouri-Columbia found that 6-Thioguanine can change how certain cancer cells function, weakening them so they can be killed by other drugs. This discovery could lead to future cancer treatments using combination therapy.
Low doses of Imatinib can stimulate the bone marrow to produce more innate immune cells, such as neutrophils and macrophages, to combat bacterial infections. This finding suggests that Imatinib or related drugs may be useful in treating a variety of infections in patients with weakened immune systems.
Researchers at Yale University have successfully restored memory and synaptic connections in Alzheimer's mice using the experimental cancer drug AZD05030. The treatment blocks damage caused by amyloid-beta plaques, a hallmark of Alzheimer's disease, and has led to the launch of human trials.
Researchers from Scripps Research Institute have discovered a unique mechanism of borrelidin, a natural product with wide-ranging antifungal, antibacterial, anti-malaria and anti-cancer effects. The study sheds light on the compound's inhibition of protein synthesis by occupying four distinct subsites on tRNA synthetase.
Researchers at Princess Margaret Cancer Centre successfully converted microbubble technology into nanoparticles that retain their imaging properties. The discovery has the potential to enhance drug delivery, prolong tumour visualization, and improve cancer treatment precision.
Researchers at Michigan Medicine have developed a new compound that shows promise in treating acute leukemia and may also play a role in prostate cancer. The MLL-menin interaction is a key driver of the disease, and blocking this interaction has shown potential in laboratory studies.
Researchers have developed an experimental drug, BHPI, that rapidly shrinks most tumors in a mouse model of human breast cancer. The drug works by hyperactivating the unfolded protein response pathway, driving cancer cells from using it for protection into making it a lethal pathway.
Weizmann Institute scientists identified a potential drug molecule that stops cancer cells from getting their 'mail' by blocking communication with the nucleus. This method could treat various cancers and have fewer side effects than current treatments.
A new study suggests that fasting combined with a class of cancer-inhibiting drugs can starve colorectal, breast and lung cancer cells, potentially replacing chemotherapy. The research found that this combination is equally effective in killing cancer cells.
Researchers have discovered a new function for the retinoblastoma gene, which plays a central role in stopping healthy cells from dividing uncontrollably. The gene also helps to mend broken strands of DNA by forming clusters with other proteins, opening up new approaches to cancer treatment.
A new study evaluates currently available screening tools for senior cancer patients taking too many medications. It found that a more comprehensive assessment and monitoring plan is needed to improve treatment outcomes.
A team of Singapore-based scientists identified a new signalling pathway regulating cancer internal diet. The therapy combines an old anti-malarial drug with CK1α inhibition, effectively treating colon and bladder cancers. Researchers hope to develop more potent inhibitors for this treatment.
Researchers discovered that saccharin binds to and deactivates carbonic anhydrase IX, a protein found in some aggressive cancers. This finding opens up the potential to develop novel anti-cancer drugs derived from common condiments.
Researchers found that blocking two pathways, PGE2 and PD-1, boosts T-cell function and enhances viral control in mice with chronic infections. Celecoxib, a non-steroidal anti-inflammatory drug, was also shown to improve T-cell responses.
A new study reveals a blood test that measures circulating tumour cells can predict which men are benefitting least from prostate cancer drug treatment after just 12 weeks. The test may allow doctors to switch patients to alternative treatments earlier, speeding up clinical trials and improving survival rates.
Researchers found that a combination of metformin and vitamin D3 significantly improved outcomes in animal studies, inhibiting tumor growth and reducing polyp formation. The dual-compound effect was more effective than either option alone, with modest amounts needed to achieve the benefits.
Researchers from the University of Melbourne found that genetic variation affects the protective effect of aspirin on bowel cancer risk. The study analyzed data from 8,624 participants and found that about 1 in 25 people do not benefit from taking aspirin, potentially increasing their risk.
Research links genetic changes in bowel tumours to immune system responses, suggesting potential for targeted immunotherapy treatments. Genetic profiles could be used to diagnose suitability for immunotherapies and tailor treatment plans.
Researchers discover that combining Sodium Formate with metal-based cancer treatment JS07 can greatly increase its effectiveness against ovarian cancer cells. The potent form of JS07 disrupts cancer cell's energy generation mechanism, leading to cell shutdown and potential reduction in side effects.
A pioneering class of drugs targeting BRCA breast cancer genes may also work against tumours with CLBC gene defects. Researchers found that CLBC-defective cancer cells are vulnerable to PARP inhibitor drugs, opening up new treatment possibilities for a broader group of patients.
Researchers use mathematical models to characterize tumor microenvironment, highlighting sanctuary sites as key to drug resistance. Tumor sanctuaries with little drug exposure are the source of resistant mutants.
Researchers aim to target autophagy pathway, a key enzyme involved in cancer and neurodegenerative diseases. They plan to use high-throughput screening facilities to identify new inhibitors of Ulk1, a critical on-off switch regulating the pathway.
A study published in JAMA found significant discrepancies in diagnoses of atypia and DCIS, highlighting the need for women to seek second opinions. The study involved 115 pathologists and 6,900 breast biopsy interpretations, revealing a concordance rate of 75.3% for invasive carcinoma but only 48% for atypia.
A Dartmouth investigator found an mHealth app acceptable to diverse and low-income women for breast health risk assessment. The study showed that 11 of the 15 participants preferred using the mobile health device over a paper tool.
Washington State University researchers have discovered a mechanism by which omega-3 fatty acids inhibit the growth and spread of prostate cancer cells. The findings suggest that a potential new anti-cancer drug could be developed to target this process.
A new international study has found a small subset of patients with adrenal cancer respond significantly to the investigational drug linsitinib, paving the way for personalized treatment options. The researchers plan to analyze DNA collected from the study to identify possible markers for response.
A study by MIT economist Ernst Berndt and colleagues found that the prices of leading cancer drugs increased by 10% annually from 1995 to 2013, even after adjusting for inflation and incremental health benefits. The researchers suggest that rising prices reflect a greater social tolerance for significant healthcare costs.
A study published in Nature Reviews Immunology reveals a 'window of vulnerability' for sexually transmitted infections (STIs) to infect the female reproductive tract. The researchers found that hormonal changes during the menstrual cycle create an optimal environment for implantation, which also increases susceptibility to STIs.
Researchers have developed spherical nucleic acids that can selectively trigger the immune response, potentially treating a range of diseases including psoriasis, lupus, rheumatoid arthritis, lymphoma, bladder cancer, and prostate cancer. SNAs are nontoxic, potent, and efficiently deliver nucleic acids into cells via the endosome.
A new study from the University of British Columbia suggests that Canada can implement universal public drug coverage without increasing taxes. The study estimates that this system would save the Canadian economy $7.3 billion annually by increasing the use of generic drugs and negotiating lower prices with pharmaceutical companies.
A study by Mayo Clinic Cancer Center reveals the average price of cancer drugs in the US has increased significantly over the years, affecting patient care. The authors recommend six potential solutions to control high drug costs, including allowing Medicare to negotiate prices and implementing value-based pricing.
Pazopanib, a cancer drug, shows promise in reducing bleeding and small AVMs in patients with hereditary hemorrhagic telangiectasia (HHT), a rare genetic disorder. The study aims to assess the efficacy of pazopanib in improving symptoms and quality of life for HHT patients.
A genetically engineered immunotoxin called DT2219 has shown safety and clinical effectiveness in a phase I trial for patients with relapsed/refractory B-cell malignancies. Two patients achieved durable objective responses, highlighting the potential of this new treatment approach.
The NCCN Clinical Practice Guidelines in Oncology provide evidence-based recommendations for smoking cessation in patients with cancer. Combining pharmacologic therapy and counseling is the most effective approach, leading to improved cancer treatment effectiveness and decreased recurrence.
Researchers found that combining naproxen with omeprazole reduced bladder cancer incidence by 75% in rats. This combination may be a valuable cancer prevention strategy for those at high risk of colon, esophageal, or other cancers.
Researchers have developed a new light therapy that can reach deep tumors using nanoparticles and FDG, producing different kinds of free radicals that overwhelm tumor cells. This treatment shows promise in reducing cancer growth and increasing survival rates with minimal toxic side effects.
A Review article discusses how existing drugs like Viagra can reduce the activity of a specific chaperone protein, HSPA5/Dna K, which may lead to anti-tumor and anti-Alzheimer's disease effects. The study also reveals potential applications in treating antibiotic-resistant infections and chemotherapy-resistant cancers.
A new study has identified two distinct subtypes of childhood leukemia and found that about 13 percent of ALL cases may be successfully treated with targeted drugs. The research developed a simple lab test to determine which patients fall into the less-common subtype, opening up new hope for treatment options.